Last reviewed · How we verify
Zonegran
Zonegran is a Small molecule drug developed by Dr. Reddy's Laboratories Limited. It is currently FDA-approved for Diffuse Lewy body disease, Partial Epilepsy Treatment Adjunct. Also known as: zonisamide.
Zonegran, also known as Zonisamide, is a small molecule that acts as a sodium channel alpha subunit blocker. It is used to treat the symptoms of epilepsy and Parkinson's disease, and is being studied as a potential treatment for post-traumatic stress disorder, alcohol use disorder, sleep apnea, obstructive sleep apnea, and obesity.
At a glance
| Generic name | Zonegran |
|---|---|
| Also known as | zonisamide |
| Sponsor | Dr. Reddy's Laboratories Limited |
| Target | Amine oxidase [flavin-containing] B, Carbonic anhydrase 1, Carbonic anhydrase 12 |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
- Diffuse Lewy body disease
- Partial Epilepsy Treatment Adjunct
Common side effects
- Somnolence
- Anorexia
- Dizziness
- Ataxia
- Agitation/Irritability
- Difficulty with memory and/or concentration
- Fatigue
- Nausea/Vomiting
- Weight loss
- Mental slowing
- Accidental injury
- Asthenia
Serious adverse events
- Lupus erythematosus
- Pulmonary embolus
- Heart failure
- Atrial fibrillation
- Thrombocytopenia
- Cholestatic jaundice
- Hematemesis
- Hyponatremia
- Syncope
- Thrombophlebitis
Key clinical trials
- Study of the Pharmacokinetics, Safety, and Tolerability of ZONISADE in Children 1 Month to 17 Years of Age With Partial-onset Seizures (PHASE4)
- Noise-Induced Hearing Loss-Acute Exposure Treatment (UA) (PHASE2)
- The Effects of Combination Zonisamide and Bupropion on Switching to an Electronic Cigarette (PHASE3)
- Population Pharmacokinetics of Antiepileptic in Pediatrics
- Low vs. Standard Daily Doses of Antiepileptic Drugs in Newly Diagnosed, Previously Untreated Epilepsy(STANDLOW) (PHASE4)
- A Clinical Study on the Efficacy and Safety of Zonisamide as a First Add-On Treatment in Epileptic Seizures (PHASE4)
- Noise-Induced Hearing Loss-Acute Exposure Treatment (PHASE2)
- The Zonisamide and Reinforcement for Reducing Alcohol Use (ZARRA) Study (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Zonegran CI brief — competitive landscape report
- Zonegran updates RSS · CI watch RSS
- Dr. Reddy's Laboratories Limited portfolio CI
Frequently asked questions about Zonegran
What is Zonegran?
What is Zonegran used for?
Who makes Zonegran?
Is Zonegran also known as anything else?
What development phase is Zonegran in?
What are the side effects of Zonegran?
What does Zonegran target?
Related
- Target: All drugs targeting Amine oxidase [flavin-containing] B, Carbonic anhydrase 1, Carbonic anhydrase 12
- Manufacturer: Dr. Reddy's Laboratories Limited — full pipeline
- Therapeutic area: All drugs in Neuroscience
- Indication: Drugs for Diffuse Lewy body disease
- Indication: Drugs for Partial Epilepsy Treatment Adjunct
- Also known as: zonisamide
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing